VASOSTRICT

Peak

vasopressin

NDAINTRAVENOUSSOLUTION
Approved
Apr 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
11

Clinical Trials (5)

NCT04789148Phase 1Recruiting

Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency

Started Sep 2025
40 enrolled
Vasopressin Deficiency
NCT06464510Phase 3Recruiting

Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis

Started Nov 2024
2,800 enrolled
Septic Shock
NCT05958342Phase 2Recruiting

CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial

Started Jun 2024
1,050 enrolled
TraumaHemorrhage
NCT02526914N/AUnknown

Effects of Intranasal Oxytocin and Vasopressin on Social Behavior and Decision Making

Started Oct 2015
432 enrolled
Healthy
NCT01611935Phase 2Completed

AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock

Started May 2013
101 enrolled
Traumatic Shock

Loss of Exclusivity

LOE Date
Jan 30, 2035
108 months away
Patent Expiry
Jan 30, 2035

Patent Records (5)

Patent #ExpiryTypeUse Code
10010575
Jan 30, 2035
U-1857
12186362
Jan 30, 2035
Product
9375478
Jan 30, 2035
U-1857
9687526
Jan 30, 2035
U-1857
9744209
Jan 30, 2035
U-1857